Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3225-3232

  Michael, Claudia ^a   Bierbach, Uta ^b   Frenzel, Katrin ^b   Lange, Thoralf ^a   Basara, Nadezda ^a   Niederwieser, Dietger ^a   Mauz Körholz, Christine ^c   Preiss, Rainer ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; IMMUNOCOMPROMISED PATIENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMIC MYCOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL DISORDER; VOMITING;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 77955403893     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01731-09     Document Type: Article

References (32)

1. Ascioglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, and T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14.
2. Boyd, A. E., S. Modi, S. J. Howard, C. B. Moore, B. G. Keevil, and D. W. Denning. 2004. Adverse reactions to voriconazole. Clin. Infect. Dis. 39:1241-1244.
3. Brüggemann, R. J. M., J. P. Donnelly, R. E. Aarnoutse, A. Warris, N. M. A. Blijlevens, J. W. Mouton, P. E. Verweij, and D. M. Burger. 2008. Therapeutic drug monitoring of voriconazole. Ther. Drug Monit. 30:403-411.
4. Clancy, C. J., and M. H. Nguyen. 1998. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17:573-575.
5. Cuenca-Estrella, M., J. R. Rodríguez-Tudela, E. Mellado, J. V. Martínez-Suárez, and A. Monzón. 1998. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J. Antimicrob. Chemother. 42:531-533.
6. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
7. Destino, L., D. A. Sutton, A. L. Helon, P. L. Havens, J. G. Thometz, R. E. Willoughby, Jr., and M. J. Chusid. 2006. Severe osteomyelitis caused by Myceliophthora thermophila after a pitchfork injury. Ann. Clin. Microbiol. Antimicrob. 5:21.
8. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
9. Espinel-Ingroff, A., E. Canton, D. Gibbs, and A. Wang. 2007. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole. J. Clin. Microbiol. 45:858-864.
10. Espinel-Ingroff, A., K. Boyle, and D. J. Sheehan. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115.
11. George, D., P. Miniter, and V. T. Andriole. 1996. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 40:86-91.
12. Imhof, A., D. J. Schaer, U. Schanz, and U. Schwarz. 2006. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med. Wkly. 136:739-742.
13. Karlsson, M. O., I. Lutsar, and P. A. Milligan. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53:935-944.
14. Lazarus, H. M., J. L. Blumer, S. Yanovich, H. Schlamm, and A. Romero. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402.
15. Lutsar, I., M. R. Hodges, K. Tomaszewski, P. F. Troke, and N. D. Wood. 2003. Safety of voriconazole and dose individualization. Clin. Infect. Dis. 36:1087-1088.
16. Michael, C., U. Bierbach, K. Frenzel, T. Lange, N. Basara, D. Niederwieser, C. Mauz-Körholz, and R. Preiss. 2010. Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults. Ther. Drug Monit. 32:194-199.
17. Michael, C., J. Teichert, and R. Preiss. 2008. Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 865:74-80.
18. Neely, M., T. Rushing, A. Kovacs, R. Jelliffe, and J. Hoffman. 2009. Voriconazole population pharmacokinetics and pharmacodynamics in children, abstr, 1488, p. 18. In Abstracts of the Annual Meeting of the Population Approach Group in Europe. http://www.page-meeting.org/default.asp?abstract=1488.
19. Neely, M., T. Rushing, A. Kovacs, R. Jelliffe, and J. Hoffman. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
20. Pascual, A., T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
21. Pasqualotto, A. C., M. Shah, R. Wynn, and D. W. Denning. 2008. Voriconazole plasma monitoring. Arch. Dis. Child. 93:578-581.
22. Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. Dupont, J. Torre-Cisneros, G. Just-Nubling, H. T. Schlamm, I. Lutsar, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
23. Purkins, L., N. Wood, K. Greenhalgh, D. E. Malcolm, D. O. Stuart, and D. Nichols. 2003. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56:2-9.
24. Purkins, L., N. Wood, K. Greenhalgh, M. J. Allen, and S. D. Oliver. 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56:10-16.
25. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
26. Steinbach, W. J., and D. K. Benjamin. 2005. New antifungal agents under development in children and neonates. Curr. Opin. Infect. Dis. 18:484-489.
27. Tan, K., N. Brayshaw, K. Tomaszewski, P. Troke, and N. Wood. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243.
28. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
29. Walsh, T. J., I. Lutsar, T. Driscoll, B. DuPont, M. Roden, P. Gharamani, M. Hodges, A. H. Groll, and J. R. Perfect. 2002. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21:240-248.
30. Walsh, T. J., M. O. Karlsson, T. Driscoll, A. G. Arguedas, P. Adamson, X. Saez-Llorens, A. J. Vora, A. C. Arrieta, J. Blumer, I. Lutsar, P. Milligan, and N. Wood. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after singe- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-2172.
31. Wood, N., K. Tan, L. Purkins, G. Layton, J. Hamlin, D. Kleinermans, and D. Nichols. 2003. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56:56-61.
32. Zonios, D. I., J. Gea-Banacloche, R. Childs, and J. E. Bennett. 2008. Hallucinations during voriconazole therapy. Clin. Infect. Dis. 47:e7-e10.